Iqvia initiated with an Outperform at RBC Capital

RBC Capital initiated coverage of Iqvia with an Outperform rating and $275 price target. Iqvia is the largest global contract research organization, helping its biopharma clients bring drugs to market more quickly by leveraging its proprietary data, software and globally-scaled services, the analyst tells investors in a research note. The firm sees “fading headwinds” setting the stage for a meaningful earnings reacceleration, which should also help re-rate Iqvia’s valuation back toward its historical average.